title: [Antibacterial activity of carumonam and cefpirome on hospital strains resistant to gentamicin and cephalothin: comparison with other beta-lactam antibiotics, new fluoroquinolones, aminoglycosides and other antibiotics].
abstract: The antibacterial in vitro activity of carumonam, a new monobactam, and cefpirome, a new cephalosporin, was studied on 483 hospital strains resistant to gentamicin and cephalothin, in comparison with amikacin, azlocillin, aztreonam, cefmenoxim, cefoperazone, cefotaxim, cefsulodin (for Pseudomonas), ceftazidime, ceftriaxone, cefuroxim, chloramphenicol, ciprofloxacin, doxycycline, enoxacin, netilmicin, norfloxacin, pefloxacin, piperacillin, rifampicin, tobramycin and trimethoprim. In general the two compounds have a very good in vito activity on Enterobacteriaceae but are less active on non-fermenting microorganisms. For the Enterobacteriaceae the minimal inhibitory concentrations 90% for carumonam was less than or equal to 1.1 mg/l excepted for Enterobacter spp. (43,6 mg/l) and M. morganii (56.8 mg/l) . All the Enterobacteriaceae are susceptible to cefpirome (minimal inhibitory concentrations 90% less than or equal to 5.3 mg/l). The activity of carumonam and cefpirome on Enterobacteriaceae is comparable with that of the third generation cephalosporins. Carumonam is more active than cefpirome and other beta-lactams, ceftazidime excepted, on Pseudomonas aeruginosa and Pseudomonas spp. On the other hand, both compounds reveal to have only a low activity on the other non-fermenters which minimal inhibitory concentrations 90% values of 115.4 mg/l for carumonam and 32.0 mg/l for cefpirome.
authors.affiliation: Institut Pasteur du Brabant, Unité des Antibotiques, Bruxelles, Belgique.
authors.forename: R
authors.initials: R
authors.lastname: Vanhoof
authors.forename: H J
authors.initials: HJ
authors.lastname: Nyssen
authors.forename: E
authors.initials: E
authors.lastname: Nulens
authors.forename: E
authors.initials: E
authors.lastname: Roebben
authors.forename: J M
authors.initials: JM
authors.lastname: Hubrechts
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001398:Aztreonam / Q000031:analogs & derivatives* / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D002512:Cephalothin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D005839:Gentamicins / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D066298:In Vitro Techniques; D015363:Quinolones / Q000494:pharmacology; D000097572:Cefpirome
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001398:Aztreonam; D002511:Cephalosporins; D002512:Cephalothin; D005839:Gentamicins; D015363:Quinolones; D000097572:Cefpirome; C044145:carumonam
vernacular_title: Activité antibactérienne du carumonam et du cefpirome sur des souches hospitalières résistantes à la gentamicine et la céfalotine:comparaison avec d'autres bêta-lactamines, de nouvelles fluoroquinolones, aminoglycosides et d'antibiotiques divers.